Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Clinuvel Pharmaceuticals Ltd
CUVCurrent price
13.53 AUD
-0.1 AUD (-0.73%)
Last closed
13.69 AUD
Company
www.clinuvel.com
ISIN
AU000000CUV3
Sector
Healthcare
Industry
Biotechnology
Exchange
Australian Securities Exchange
Capitalization
686 609 115 AUD
Yield for 12 month
-18.44 %
1Y
3Y
5Y
10Y
15Y
CUV
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. Address: 535 Bourke Street, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
40.77 AUDP/E ratio
19.3Dividend Yield
0.38 %Current Year
+89 519 790 AUD
Last Year
+79 512 842 AUD
Current Quarter
+56 218 894 AUD
Last Quarter
+32 747 618 AUD
Current Year
+79 285 013 AUD
Last Year
+51 359 093 AUD
Current Quarter
+50 848 439 AUD
Last Quarter
+17 177 789 AUD
Key Figures CUV
1 year
3 years
5 years
10 years
EBITDA
50 072 308 AUD
Operating Margin TTM
PE Ratio
19.3
Return On Assets TTM
14.29 %
PEG Ratio
–
Return On Equity TTM
19.39 %
Wall Street Target Price
40.77 AUD
Revenue TTM
89 519 786 AUD
Book Value
4.12 AUD
Revenue Per Share TTM
Dividend Share
0.051 AUD
Quarterly Revenue Growth YOY
13.1 %
Dividend Yield
0.38 %
Gross Profit TTM
71 877 358 AUD
Earnings per share
0.71 AUD
Diluted Eps TTM
0.71 AUD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
31.9 %
Profit Margin
40.41 %
Dividend Analytics CUV
Dividend growth over 5 years
150 %Continuous growth
2 yearsPayout Ratio 5 years average
8 %Dividend History CUV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
0.05
Ex Dividend Date
05.09.2024
Forward Annual Dividend Yield
0.36 %
Last Split Factor
1:10
Payout Ratio
7.16 %
Last Split Date
12.11.2010
Dividend Date
–
Stock Valuation CUV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
19.3
Forward PE
19.3424
Enterprise Value Revenue
5.7026
Price Sales TTM
7.6699
Enterprise Value EBITDA
8.9354
Price Book MRQ
3.3783
Financials CUV
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CUV
For 52 weeks
13.11 AUD
18.42 AUD
50 Day MA
14.59 AUD
Shares Short Prior Month
–
200 Day MA
14.97 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart